Fly News Breaks for July 24, 2019
Jul 24, 2019 | 15:36 EDT
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $69 price target on Integra LifeSciences after the company reported Q2 earnings results that were "ahead of expectations," with guidance the analyst believes is "likely conservative." O'Brien was also positive that the company's integration efforts look to be moving in the right direction, that orthopedics growth is improving, and that management remains committed to 100bps of GM expansion. He said Integra "now has a more favorable setup for the year (still at an attractive valuation)."
News For IART From the Last 2 Days
There are no results for your query IART